Cancer Stem Cell Markers and Prognostic Markers in Circulating Tumor Cells
Stopped early
Conditions studied: Colorectal Cancer
In brief
The study will enroll patients with metastatic colorectal cancer receiving chemotherapy. A total of approximately 22 cc of blood will be drawn during various chemotherapy infusions. Additional proposed laboratory studies may unravel important biological insights into the relationship of circulating tumor cell genomic and genetic profiles as they compare to the primary tumors. Additionally the investigators hope to gain an understanding of potential subgroups of patients that have very high numbers of circulating tumor cells or those with early relapse of circulating tumor cells after early reduction of circulating tumor cell numbers.
Key facts
- Study ID
- NCT01286883
- Run by
- Milton S. Hershey Medical Center
- People needed
- 33
- Starts
- 2011-02-01
- Expected to finish
- 2014-09-01
- Last updated by the study team
- 2018-08-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients with the diagnosis of metastatic colorectal cancer, either newly diagnosed or recurrent, with measurable disease that has not been irradiated within the last 5 weeks.
- Age > 18 years old
- ECOG performance status 0-3
You may not qualify if…
- Patients who have received prior therapy in the last 5 weeks
- Ongoing therapy with a particular regimen that was initiated prior to enrollment and lack of availability of baseline CTC evaluation
- Patient with concurrent diagnosis of other active solid malignancies will be exclude
- Patient life expectancy of less than six weeks
Where it is running
- Penn State Milton S. Hershey Medical Center — Hershey, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.